In 2007, the agency approved Lialda, generically known as mesalamine, for induction of remission in patients with active, mild to moderate ulcerative colitis.
Read the Shire Pharmaceuticals release on Lialda.
Read the FDA statement about Lialda.
Related Articles on FDA Approvals:
FDA Approves Lazanda Nasal Spray for Cancer Pain
FDA Clears New Version of PillCam for Esophageal Mucosa
St. Jude Gets FDA Approval for Epiducer Neurostimulation Delivery System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.